90Y-epratuzumab tetraxetan

DRUG3 trials

Sponsors

Gilead Sciences, Weill Medical College of Cornell University, Nantes University Hospital

Conditions

Aggressive NHLCD22+ Relapsed/Refractory B-ALLDiffuse Large B-cell LymphomaFollicular LymphomaNHLNon Hodgkin's Lymphoma

Phase 1

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

WithdrawnNCT01101581

Gilead SciencesAggressive NHL, Diffuse Large B-cell Lymphoma, NHL +1

Start: 2010-05-31End: 2017-03-31Updated: 2021-08-18

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

TerminatedNCT01147393

Weill Medical College of Cornell UniversityFollicular Lymphoma

Start: 2010-10-31End: 2015-07-31Updated: 2018-02-22

Phase 2

Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL

WithdrawnNCT02844530

Nantes University HospitalCD22+ Relapsed/Refractory B-ALL

End: 2017-01-31Updated: 2017-01-19